The clinical data for each patient are summarized in Table 1. The ocular diagnoses included scleritis (n = 8), scleritis and anterior uveitis (n = 1), scleritis and panuveitis (n = 1), anterior uveitis (n = 8), panuveitis (n = 3), retinal vasculitis and panuveitis (n = 5), and OCP (n = 1). Twenty-one patients had underlying systemic diagnoses, which included rheumatoid arthritis (n = 2), juvenile idiopathic arthritis (n = 5), ankylosing spondylitis (n = 2), Behçet disease (n = 6), reactive arthritis (n = 2), relapsing polychondritis (n = 1), Crohn disease (n = 1), psoriasis (n = 1), and mucous membrane pemphigoid (n = 1). Five of these patients with systemic disease were HLA-B27 positive. The mean patient age was 37.3 years (range, 6-66 years). The mean number of infliximab infusions was 15.6 (range, 4-45), and the mean follow-up time from the first infusion was 25.6 months (range, 4-62 months). While all patients had active ocular inflammation, patients 1, 11, 14, 16, and 17 received infliximab primarily for joint inflammation and the remaining 22 patients received infliximab primarily for ocular inflammation.